Vivus

Vivus (OTC Pink: VVUSQ) is a small pharmaceutical company headquartered in Campbell, California, working in obesity, sleep, and sexual health. Vivus is developing an erectile dysfunction drug, Avanafil, that has completed Phase 3 clinical trials.[1] The drug has been approved for use by the FDA, and will be sold under the trademark name Stendra.[2] Stendra is the first and only oral ED treatment approved to be taken approximately 15 minutes before sexual activity.[3]

A documentary movie "Orgasm Inc." was made at Vivus in 2009 to document the process of creating a treatment for Female sexual arousal disorder (FSD).

Vivus also developed an obesity drug, Qnexa (now called Qsymia), a combination of phentermine and topiramate, two existing weight-loss drugs.[4] On July 17, 2012, The U.S. Food and Drug Administration approved Qsymia (phentermine and topiramate extended-release), made by Vivus, as an addition to a reduced-calorie diet and exercise for chronic weight management. The drug was approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).[5][6]

In 2016, the company was ranked #23 on the Deloitte Fast 500 North America list.[7]

In 2020, the company filed for bankruptcy protection.[8]

References
  1. Phase 3 Data on VIVUS' Avanafil for Erectile Dysfunction to be Featured at the AUA 2010 Annual Meeting, ""
  2. "Most Popular in Your Life". USA Today.
  3. "VIVUS and Auxilium Announce Stendra Label Expansion". Zacks Investment Research.
  4. Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP), ""
  5. Hellmich, Nancy (17 July 2012). "New diet drug helps patients lose about 10% of weight". USA Today. Retrieved 17 July 2012.
  6. "Medications Target Long-Term Weight Control". FDA.gov. Retrieved 17 July 2012.
  7. "2016 Winners by rank" (PDF). Deloitte. Retrieved 14 October 2017.
  8. "Drugmaker Vivus Files for Bankruptcy in Deal With IEH". The Wall Street Journal. July 7, 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.